Nasus Pharma is trading at $3.05, down 5.86% in pre-market, with no company-specific catalyst identified.
- No new company-specific announcement explaining the October 21 pre-market decline surfaced in the search; the latest company release listed was September 29, about Phase 1 dosing of NS003.
- Major indices and futures are higher, so broad market weakness does not explain the drop.
- The decline follows several modestly higher closes; pre-market trading volume or activity details were unavailable in the sources reviewed.